Advanced search
Publication Cover
Future Neurology Volume 1, 2006 - Issue 3
Submit an article Journal homepage
65
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Ropinirole: use in restless legs syndrome

Luigi Ferini-StrambiSan Raffaele Vita-Salute University, Sleep Disorders Center, Via Stamira d‘ Ancona 20, 20127Milano, Italy. [email protected]
Pages 269-276 | Published online: 21 Apr 2006

Bibliography

  • Montplaisir J , AllenR, WaltersSA, Ferini-StrambiL: Restless legs syndrome and periodic limb movements during sleep. In:Principles and Practice of Sleep Medicine, Fourth Edition. Kryger M, Roth T, Dement W (Eds). Elsevier-Saunders, Philadelphia, PA, USA, 839–852 (2005).
  • Walters AS : International Restless Legs Syndrome Study Group: Toward a better definition of the restless legs syndrome.Mov. Disord.10, 634–642 (1995).
  • Allen RP , PicchiettiD, HeningWA, TrenkwalderC, WaltersAS, MontplaisirJ: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology: a report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.Sleep Med.4, 101–119 (2003).
  • Atlas Task Force of the American Sleep Disorders Association: Recording and scoring of leg movements. Sleep16, 748–759 (1993).
  • Hening W , WaltersAS, AllenRP, MontplaisirJ, MyersA, Ferini-StrambiL: Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS Epidemiology, Symptoms, and Treatment) primary care study.Sleep Med.5, 237–246 (2004).
  • Berger K , LuedemannJ, TrenkwalderC, JohnU, KesslerC: Sex and the risk of restless legs syndrome in the general population.Arch. Intern. Med.164, 196–202 (2004).
  • Allen R , WaltersAS, MontplaisirJet al.: Restless legs syndrome prevalence and impact: REST general population study. Arch. Intern. Med.165, 1286–1292 (2005).
  • Connor JR , WangXS, PattonSMet al.: Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. Neurology62, 1563–1567 (2004).
  • Michaud M , DumontM, SelmaouiB, PaquetJ, FantiniML, MontplaisirJ: Circadian rhythm of restless legs syndrome: relationship with biological markers.Ann. Neurol.55(3), 372–380 (2004).
  • Allen RP , BarkerPB, WehrlF, SongHK, EarleyCJ: MRI measurement of brain iron in patients with restless legs syndrome.Neurology56, 263–265 (2001).
  • Thorpy MJ : New paradigms in the treatment of restless legs syndrome.Neurology64(Suppl. 3), S28–S33 (2005).
  • Akpinar S : Treatment of restless legs syndrome with levodopa plus benserazide.Arch. Neurol.39(11), 739 (1982).
  • Comella CL : Restless legs syndrome. Treatment with dopaminergic agents.Neurology58(Suppl. 1), S87–S92 (2002).
  • Stiasny K , WetterTC, TrenkwalderC, OertelWH: Restless legs syndrome and its treatment by dopamine agonists.Parkinsonism Relat. Disord.7, 21–25 (2001).
  • Garcia-Borreguero D : Augmentation: understanding a key feature of RLS.Sleep Med.5, 5–6 (2004).
  • Stiasny K , WetterTC, WinkelmannJet al.: Long-term effects of pergolide in the treatment of restless legs syndrome. Neurology56, 1399–1402 (2001).
  • Earley CJ , AllenRP: Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients.Sleep19, 801–810 (1996).
  • Trenkwalder C , HundemerHP, LledoAet al.: Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS study. Neurology62(8), 1391–1397 (2004).
  • Bleumink GS , van der Molen-Eijgenraam M, Strijbos JH, Sanwikarja S, van Puijenbroek EP, Stricker BH: Pergolide-induced pleuropulmonary fibrosis. Clin. Neuropharmacol.25, 290–293 (2002).
  • Danoff SK , GrassoME, TerryPB, FlynnJA: Pleuropulmonary disease due to pergolide use for restless legs syndrome.Chest120, 313–316 (2001).
  • Horvath J , FrossRD, Kleiner-GismanGet al.: Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord.19, 656–662 (2004).
  • Baseman DG , O‘SuilleabhainPE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr: Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology63, 301–304 (2004).
  • Montplaisir J , NicholsA, DenesleR, Gomez-MancillaB: Restless legs syndrome improved by pramipexole: a double-blind randomized trial.Neurology52, 938–943 (1999).
  • Partinen M , HirvonenK, AlakuijalaA, Jama L, Terttunen J: Pramipexole is safe and efficacious in the treatment of idiopathic restless legs syndrome: results of a large randomized double-blind, placebo-controlled, dose-finding study. Sleep27, A293–A294 (2004) (Abstract).
  • GlaxoSmithKline: Requip® Package Insert (2001).
  • Kuzel MD : Ropinirole: a dopamine agonist for the treatment of Parkinson‘s disease.Am. J. Health Syst. Pharm.56(3), 217–224 (1999).
  • Kaye CM , NichollsB: Clinical pharmacokinetics of ropinirole.Clin. Pharmacokinet.39(4), 243–254 (2000).
  • Pellecchia MT , VitaleC, SabatiniMet al.: Ropinirole as a treatment of restless legs syndrome in patients on chronic hemodialysis: an open randomized crossover trial versus levodopa sustained release. Clin. Neuropharmacol.27(4), 178–181 (2004).
  • Adler CH , SethiKD, HauserRAet al.: Ropinirole for the treatment of early Parkinson‘s disease.Neurology49, 393–399 (1997).
  • Korczyn AD , BruntER, LarsenJPet al.: A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson‘s disease. Neurology53, 364–370 (1999).
  • Whone AL , WattsRL, StoesslAJet al.: Slower progression of Parkinson‘s disease with ropinirole versus levodopa: the REAL-PET study. Ann. Neurol.54, 93–101 (2003).
  • Matheson AJ , SpencerCM: Ropinirole: a review of its use in the management of Parkinson‘s disease.Drugs60, 115–137 (2000).
  • Jost WH : Ropinirole: current status of the studies.J. Neurol.251(Suppl. 6), 13–18 (2004).
  • Frucht S , RogersJD, GreenePEet al.: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology52, 1908–1910 (1999).
  • Razmy A , LangAE, ShapiroCM: Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists.Arch. Neurol.61, 97–102 (2004).
  • Saletu B , GruberG, SaletuMet al.: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 1. Findings on objective and subjective sleep and awakening quality. Neuropsychobiology41(4), 181–189 (2000).
  • Saletu M , AndererP, SaletuBet al.: Sleep laboratory studies in restless legs syndrome patients as compared with normals and acute effects of ropinirole. 2. Findings on periodic leg movements, arousals, and respiratory variables.Neuropsychobiology41(4), 190–199 (2000).
  • Estivill E , De la Fuente V: The efficacy of ropinirole in the treatment of chronic insomnia secondary to restless legs syndrome: polysomnography data. Revista de Neurologia29(9), 805–807 (1999).
  • Ondo W : Ropinirole for restless legs syndrome.Mov. Disord.14(1), 138–140 (1999).
  • Estivill E , De la Fuente V, Barraquer A, Cilveti R: Use of ropinirole as a treatment of 10 patients with restless legs syndrome. J. Sleep Res.7(2), 80 (1998) (Abstract).
  • Galvez-Jimenez N , KhanT: Ropinirole and restless legs syndrome.Mov. Disord.14(5), 890–892 (1999).
  • Trenkwalder C , Garcia-BorregueroD, MontagnaPet al.: Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo-controlled study in 10 European countries. J. Neurol. Neurosurg. Psychiatry75, 92–97 (2004).
  • Walters AS , OndoWG, DreykluftTet al.: Ropinirole is effective in the treatment of RLS. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov. Disord.19(12), 1411–1423 (2004).
  • Bogan RK , FryJM, SchmidtMH, Carson SW, Ritchie SY: Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin. Proc.81(1), 17–27 (2006).
  • Adler CH , HauserRA, SethiKet al.: Ropinirole for restless legs syndrome: a placebo controlled crossover trial. Neurology62, 1405–1407 (2004).
  • Montplaisir J , KarraschJ, HaanJ, Kruger AJ, Volc D: The impact of ropinirole treatment on RLS symptoms and health related quality of life (HRQOL) in patients with RLS: results of a multinational 36-week study. Sleep27, A293 (2004).
  • Allen R , BeckerPM, BoganRet al.: Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep27(5), 907–914 (2004).
  • Walsh BT , SeidmanSN, SyskoR, Gould M: Placebo response in studies of major depression: variable, substantila and growing. JAMA287, 1840–1847 (2002).
  • Bliwise DL , FreemanA, IngramCDet al.: Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med.6, 141–147 (2005).
  • Happe S , SauterC, KloschG, SaletuB, ZeitlhoferJ: Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome.Neuropsychobiology48, 82–86 (2003).
  • Kakar RS , KushidaCA: Ropinirole in the treatment of restless legs syndrome.Expert Rev. Neurother.5, 35–42 (2005).
  • Winkelman JW , JohnstonL: Augmentation and tolerance with long-term pramipexole treatment of RLS.Sleep Med.5(1), 9–14 (2004).
  • Ondo WG , Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J: Daytime sleepiness and other sleep disorders in Parkinson‘s disease. Neurology57(8), 1392–1396 (2001).
  • Pal S , BhattacharyaKF, ApapitoC, ChaudhuriKR: A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson‘s disease taking pramipexole, cabergoline and levodopa mono and combination therapy.J. Neurol. Transm.108(1), 71–77 (2002).
  • Hobson DE , LangAE, MartinWRet al.: Excessive daytime sleepiness and sudden onset sleep in Parkinson‘s disease: a survey by Canadian Movement Disorders Group. JAMA287(4), 455–463 (2002).
  • Rye DB , BliwiseDL, DiheniaB, GurekiP: Daytime sleepiness in Parkinson‘s disease.J. Sleep Res.9(1), 63–69 (2000).
  • Bonuccelli U : Comparing dopamine agonists in Parkinson‘s disease.Curr. Opin. Neurol.16(Suppl. 1) S13–S19 (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.